Keyphrases
Nanocapsules
84%
Plasminogen Activator
82%
Nanoparticles
61%
Urokinase-type Plasminogen Activator
56%
Urokinase
52%
Superoxide Dismutase Mimic
46%
Low-density Lipoprotein Receptor
42%
Endothelial Dysfunction
42%
Tempol
39%
Microparticles
37%
Plasminogen Activator inhibitor-1 (PAI-1)
37%
Diabetic Rats
36%
Smooth muscle Contraction
34%
Tacrolimus
32%
Lipoproteins
30%
Low-density Lipoprotein
29%
N-methyl-D-aspartate Receptor (NMDAR)
28%
Nanoencapsulation
28%
Vascular Permeability
28%
Diabetes
27%
Acetylcholine
26%
Substrate Drugs
26%
Glucagon
26%
Exenatide
26%
P-glycoprotein Substrate
26%
Streptozotocin-induced Diabetic Rats
26%
Enhanced Bioavailability
26%
Oxaliplatin
26%
Vascular Cells
26%
Antibody Conjugates
26%
Pharmacology, Toxicology and Pharmaceutical Science
Nanoparticle
100%
Nanocapsule
83%
Plasminogen Activator
72%
Urokinase
52%
Superoxide Dismutase
52%
Receptor
49%
Endothelial Dysfunction
42%
Tacrolimus
39%
Drug Delivery System
39%
Bioavailability
36%
Microparticle
35%
Palmitic Acid
33%
Low Density Lipoprotein
30%
P-Glycoprotein
28%
Nanoemulsion
28%
Diabetes Mellitus
28%
Lung Cancer
27%
Plasminogen Activator Inhibitor 1
27%
Oxaliplatin
26%
Thrombocyte Factor 4
26%
Docetaxel
26%
Streptozotocin
26%
Tempol
26%
Exendin 4
26%
Ciclosporin
26%
Antibody Conjugate
26%
Acetylcholine
25%
Superoxide
24%
Inflammation
23%
Tissue Plasminogen Activator
22%